Keywords
epidemiology
Panama
How to Cite
Abstract
Introduction. Non-Hodgkin lymphomas (NHL) represent approximately 3% of all cancers diagnosed worldwide and, within lymphoid neoplasms, they represent 90% of all cases. Panama does not have any epidemiological study on NHL and no data has been published that demonstrates our reality regarding this neoplastic entity, so it is necessary to know the data on this heterogeneous entity. Material and methods. Observational, retrospective, analytical, cross-sectional study carried out in a third level complexity center. The study sample corresponds to 196 patients. The records of each of the cases were evaluated. The information collected was analyzed using the SPSS 25.0 program. The main objective is to determine the clinical and epidemiological characteristics of patients with B-cell NHL included in the study. Results. 53% of the patients were male and 47% were female. 74.8% debuted in advanced stages of the disease, associated with a similar percentage reporting B symptoms. Diffuse large B cell lymphoma represents the most common subtype with more than 60% of registered cases. LDH values >500 U/L and the presence of B symptoms were associated with lower overall survival. Discussion. The epidemiological, clinical and therapeutic characteristics of our population are similar to those described in the region, however there is a greater proportion of patients who debut with B symptoms and advanced stages of the disease. It was possible to validate in our population poor prognostic factors that were described in other latitudes.
References
Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin's Lymphoma. Med Sci (Basel). 2021 Jan 30;9(1):5. doi:10.3390/medsci9010005
Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848-857 3. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Pat- more R, et al. Lymphoma incidence, survival and
prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575-1584
Álvarez-Alvarado AM, López-Barquero A, Buitrón N, Quiel D, Cumba T, Matos C, Vasallo R, Torselli S. Análisis de la incidencia del linfoma difuso de células B grandes y el linfoma folicular en tres países de América Central y el Caribe (República Dominicana, Guatemala y Panamá). Hematol Méx. 2022; 23 (3): 131-145.
Hernandez E, Alvarado-Ibarra M, Lien-Chang LE, et al. Epidemiology and Clinical Characteristics of Non-Hodgkin Lymphoma in Mexico. World J Oncol. 2021 Feb;12(1):28-33. doi: 10.14740/wjon1351.
Vite, L. Linfoma no Hodgkin: perfil clinico, epidemiologico y sus complicaciones en pacientes adultos mayores atendidos en Instituto Oncologico Nacional “Dr. Juan Tanca Marengo” periodo 2012-2015. 2017. Universidad de Guayaquil
American Cancer Society: Cancer Facts & Statistics (no date) American Cancer Society | Cancer Facts & Statistics.
Cecilia Radkiewicz, Johanna Borg Bruchfeld, Caroline Weibull et al. Sex Differences in Lymphoma Incidence and Excess Mortality By Subtype: A Comprehensive National Study. Blood. 2021;138 (Supplement 1): 2534. ISSN 0006-4971. Disponible en: https://doi.org/10.1182/blood-2021-146604
Perry AM, Diebold J, Nathwani BN et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016 Oct;101(10):1244-1250. doi: 10.3324/haematol.2016.148809
Hernandez-Ruiz E, Alvarado-Ibarra M, Juan LienChang LE, et al. Epidemiology and Clinical Characteristics of Non-Hodgkin Lymphoma in Mexico. World J Oncol. 2021 Feb;12(1):28-33. doi: 10.14740/wjon1351
Cuenta de Alto Costo. Consenso basado en evidencia.
Indicadores de gestión del riesgo en pacientes con linfoma No Hodgkin y linfoma Hodgkin en Colombia [En línea]. 2018. 1-114
Leukemia and Lymphoma Society. Non-Hodgkin Lymphoma. 2017. Disponible en: https://www.lls.org/sites/default/files/file_assets/nhl.pdf
Prakash G, Sharma A, Raina V, et al. B cell non-Hodgkin's lymphoma: Experience from a tertiary care cancer center. Ann Hematol. 2012 Oct;91(10):1603-11. doi: 10.1007/s00277-012-1491-5
Hernandez E, Alvarado-Ibarra M, Lien-Chang LE et al. Epidemiology and Clinical Characteristics of Non-Hodgkin Lymphoma in Mexico. World J Oncol. 2021 Feb;12(1):28-33. doi: 10.14740/wjon1351.
Yoon DH, Choi DR, Ahn HJ et al. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol. 2010 Aug;85(2):149-57. doi: 10.1111/j.1600-0609.2010.01467.x
Alderuccio JP, Olszewski AJ, Evens AM et al. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021 Jul 27;5(14):2852-2862. doi: 10.1182/bloodadvances.2021004458.
Mantina H, Wiggill TM, Carmona S et al. Characterization of Lymphomas in a high prevalence HIV setting. J Acquir Immune Defic Syndr. 2010 Apr;53(5):656-60. doi: 10.1097/QAI.0b013e3181bf5544. Erratum in: J Acquir Immune Defic Syndr. 2010 Jun;54(2):221.
Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, Deakin DP, Crowther D. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer. 1989 Feb;59(2):276-82. doi: 10.1038/bjc.1989.57.
Qi J, Gu C, Wang W, Xiang M, Chen X, Fu J. Elevated Lactate Dehydrogenase Levels Display a Poor Prognostic Factor for Non-Hodgkin's Lymphoma
in Intensive Care Unit: An Analysis of the MIMIC-III Database Combined With External Validation. Front Oncol. 2021 Oct 28;11:753712. doi: 10.3389/fonc.2021.753712.
Matsumoto K, Fujisawa S, Ando T et al. Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study. Turk J Haematol. 2018 Aug 3;35(3):181-184. doi: 10.4274/tjh.2017.0437.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar